Last 12 months
Inside the activity.
0 purchase rows · 153 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 25 |
| Dec 2025 | 0 | 13 |
| Jan 2026 | 0 | 14 |
| Feb 2026 | 0 | 24 |
| Mar 2026 | 0 | 12 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 23 |
| Jun 2026 | 0 | 20 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 7 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
MCCORMICK FRANKChairman of Oncology
|
Exercise / conversionSeries B Units · Derivative | 66,729 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · derivative · entry 9 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,729 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F4 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by the Reporting Person. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
MCCORMICK FRANKChairman of Oncology
|
Exercise / conversionCommon Units · Derivative | 132,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · derivative · entry 8 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 132,317 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of May 6, 2015, such that the shares shall be fully vested on May 6, 2020, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
MCCORMICK FRANKChairman of Oncology
|
Exercise / conversionCommon Units · Derivative | 47,165 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · derivative · entry 7 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,165 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F2 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
MCCORMICK FRANKChairman of Oncology
|
Exercise / conversionCommon Stock | 290,476 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · nonDerivative · entry 6 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,361,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
MCCORMICK FRANKChairman of Oncology
|
Exercise / conversionCommon Stock | 418,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · nonDerivative · entry 5 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,070,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of August 15, 2017, such that the shares shall be fully vested on August 15, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
MCCORMICK FRANKChairman of Oncology
|
Exercise / conversionCommon Stock | 406,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · nonDerivative · entry 4 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 26, 2016, such that the shares shall be fully vested on March 26, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
MCCORMICK FRANKChairman of Oncology
|
Exercise / conversionCommon Stock | 66,729 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · nonDerivative · entry 3 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by the Reporting Person. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
MCCORMICK FRANKChairman of Oncology
|
Exercise / conversionCommon Stock | 132,317 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · nonDerivative · entry 2 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of May 6, 2015, such that the shares shall be fully vested on May 6, 2020, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
MCCORMICK FRANKChairman of Oncology
|
Exercise / conversionCommon Stock | 47,165 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · nonDerivative · entry 1 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
Exercise / conversionManagement Incentive Units · Derivative | 5,364 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019144 · doc4.xml · derivative · entry 9 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,364 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F5 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
Exercise / conversionManagement Incentive Units · Derivative | 151,563 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019144 · doc4.xml · derivative · entry 8 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 151,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F4 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of October 31, 2018, such that the shares shall be fully vested on October 31, 2023, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
Exercise / conversionManagement Incentive Units · Derivative | 8,420 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019144 · doc4.xml · derivative · entry 7 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of January 1, 2017, such that the shares shall be fully vested on January 1, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
Exercise / conversionManagement Incentive Units · Derivative | 8,420 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019144 · doc4.xml · derivative · entry 6 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F2 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 22, 2016, such that the shares shall be fully vested on March 22, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
PurchaseCommon Stock | 7,000 | $17.00 | $119,000.00 |
DisclosureSEC source: 0000899243-19-019144 · doc4.xml · nonDerivative · entry 5 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,767 Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
Exercise / conversionCommon Stock | 5,364 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019144 · doc4.xml · nonDerivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
Exercise / conversionCommon Stock | 151,563 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019144 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of October 31, 2018, such that the shares shall be fully vested on October 31, 2023, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
Exercise / conversionCommon Stock | 8,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019144 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of January 1, 2017, such that the shares shall be fully vested on January 1, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
Exercise / conversionCommon Stock | 8,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019144 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 22, 2016, such that the shares shall be fully vested on March 22, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionManagement Incentive Units · Derivative | 9,262 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019136 · doc4.xml · derivative · entry 4 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,262 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of October 31, 2018, such that the shares shall be fully vested on October 31, 2023, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionManagement Incentive Units · Derivative | 3,368 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019136 · doc4.xml · derivative · entry 3 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F2 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 6, 2017, such that the shares shall be fully vested on February 6, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionCommon Stock | 9,262 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019136 · doc4.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of October 31, 2018, such that the shares shall be fully vested on October 31, 2023, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionCommon Stock | 3,368 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019136 · doc4.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 6, 2017, such that the shares shall be fully vested on February 6, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionManagement Incentive Units · Derivative | 1,907,102 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · derivative · entry 14 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,907,102 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F8 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionManagement Incentive Units · Derivative | 2,744,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · derivative · entry 13 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,744,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F7 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of August 15, 2017, such that the shares shall be fully vested on August 15, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionManagement Incentive Units · Derivative | 927,686 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · derivative · entry 12 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 927,686 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F6 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by The Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purposes. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F6 · ownership.nature: Represents shares of Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by The Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purposes. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionManagement Incentive Units · Derivative | 1,742,631 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · derivative · entry 11 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,742,631 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F5 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 26, 2016, such that the shares shall be fully vested on March 26, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionSeries B Units · Derivative | 400,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · derivative · entry 10 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 400,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F4 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by Neil Kumar LLC. The Reporting Person is the sole member of Neil Kumar LLC and has sole voting, investment and dispositive power over the shares held by Neil Kumar LLC. The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purposes. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F4 · ownership.nature: Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by Neil Kumar LLC. The Reporting Person is the sole member of Neil Kumar LLC and has sole voting, investment and dispositive power over the shares held by Neil Kumar LLC. The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purposes. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionCommon Units · Derivative | 906,905 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · derivative · entry 9 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 906,905 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of May 6, 2015, such that the shares shall be fully vested on May 6, 2020, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionCommon Units · Derivative | 323,270 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · derivative · entry 8 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 323,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F2 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionCommon Stock | 927,686 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · nonDerivative · entry 7 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 927,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by The Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purposes. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F6 · ownership.nature: Represents shares of Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by The Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purposes. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionCommon Stock | 400,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · nonDerivative · entry 6 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 400,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by Neil Kumar LLC. The Reporting Person is the sole member of Neil Kumar LLC and has sole voting, investment and dispositive power over the shares held by Neil Kumar LLC. The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purposes. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F4 · ownership.nature: Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by Neil Kumar LLC. The Reporting Person is the sole member of Neil Kumar LLC and has sole voting, investment and dispositive power over the shares held by Neil Kumar LLC. The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purposes. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionCommon Stock | 1,907,102 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,624,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionCommon Stock | 2,744,459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,717,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of August 15, 2017, such that the shares shall be fully vested on August 15, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionCommon Stock | 1,742,631 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,972,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 26, 2016, such that the shares shall be fully vested on March 26, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionCommon Stock | 906,905 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,230,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of May 6, 2015, such that the shares shall be fully vested on May 6, 2020, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC |
Kumar NeilDirector · See Remarks
|
Exercise / conversionCommon Stock | 323,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019137 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:30 UTC |
KKR Genetic Disorder L.P.10% owner
ROBERTS GEORGE R10% owner
KRAVIS HENRY R10% owner
KKR Management LLP10% owner
KKR & Co. Inc.10% owner
KKR Group Holdings Corp.10% owner
KKR Management Holdings Corp10% owner
KKR Management Holdings L.P.10% owner
KKR Genetic Disorder GP LLC10% owner
|
ConversionSeries D Preferred Units · Derivative | 50,446,451 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019173 · doc4.xml · derivative · entry 5 KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner ROBERTS GEORGE R · CIK 0001081715 · 10% owner KRAVIS HENRY R · CIK 0001081714 · 10% owner KKR Management LLC · CIK 0001472694 · 10% owner KKR & Co. Inc. · CIK 0001404912 · 10% owner KKR Group Holdings Corp. · CIK 0001743754 · 10% owner KKR Management Holdings Corp · CIK 0001472692 · 10% owner KKR Management Holdings L.P. · CIK 0001472693 · 10% owner KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 10,178,954 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date. F2 · ownership.nature: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:30 UTC |
KKR Genetic Disorder L.P.10% owner
ROBERTS GEORGE R10% owner
KRAVIS HENRY R10% owner
KKR Management LLP10% owner
KKR & Co. Inc.10% owner
KKR Group Holdings Corp.10% owner
KKR Management Holdings Corp10% owner
KKR Management Holdings L.P.10% owner
KKR Genetic Disorder GP LLC10% owner
|
ConversionSeries C Preferred Units · Derivative | 36,246,893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019173 · doc4.xml · derivative · entry 4 KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner ROBERTS GEORGE R · CIK 0001081715 · 10% owner KRAVIS HENRY R · CIK 0001081714 · 10% owner KKR Management LLC · CIK 0001472694 · 10% owner KKR & Co. Inc. · CIK 0001404912 · 10% owner KKR Group Holdings Corp. · CIK 0001743754 · 10% owner KKR Management Holdings Corp · CIK 0001472692 · 10% owner KKR Management Holdings L.P. · CIK 0001472693 · 10% owner KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 8,215,295 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date. F2 · ownership.nature: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:30 UTC |
KKR Genetic Disorder L.P.10% owner
ROBERTS GEORGE R10% owner
KRAVIS HENRY R10% owner
KKR Management LLP10% owner
KKR & Co. Inc.10% owner
KKR Group Holdings Corp.10% owner
KKR Management Holdings Corp10% owner
KKR Management Holdings L.P.10% owner
KKR Genetic Disorder GP LLC10% owner
|
ConversionSeries B Preferred Units · Derivative | 81,022,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019173 · doc4.xml · derivative · entry 3 KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner ROBERTS GEORGE R · CIK 0001081715 · 10% owner KRAVIS HENRY R · CIK 0001081714 · 10% owner KKR Management LLC · CIK 0001472694 · 10% owner KKR & Co. Inc. · CIK 0001404912 · 10% owner KKR Group Holdings Corp. · CIK 0001743754 · 10% owner KKR Management Holdings Corp · CIK 0001472692 · 10% owner KKR Management Holdings L.P. · CIK 0001472693 · 10% owner KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 15,859,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date. F2 · ownership.nature: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:30 UTC |
KKR Genetic Disorder L.P.10% owner
ROBERTS GEORGE R10% owner
KRAVIS HENRY R10% owner
KKR Management LLP10% owner
KKR & Co. Inc.10% owner
KKR Group Holdings Corp.10% owner
KKR Management Holdings Corp10% owner
KKR Management Holdings L.P.10% owner
KKR Genetic Disorder GP LLC10% owner
|
PurchaseCommon Stock | 2,647,100 | $17.00 | $45,000,700.00 |
DisclosureSEC source: 0000899243-19-019173 · doc4.xml · nonDerivative · entry 2 KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner ROBERTS GEORGE R · CIK 0001081715 · 10% owner KRAVIS HENRY R · CIK 0001081714 · 10% owner KKR Management LLC · CIK 0001472694 · 10% owner KKR & Co. Inc. · CIK 0001404912 · 10% owner KKR Group Holdings Corp. · CIK 0001743754 · 10% owner KKR Management Holdings Corp · CIK 0001472692 · 10% owner KKR Management Holdings L.P. · CIK 0001472693 · 10% owner KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 36,900,661 F2 · ownership.nature: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:30 UTC |
KKR Genetic Disorder L.P.10% owner
ROBERTS GEORGE R10% owner
KRAVIS HENRY R10% owner
KKR Management LLP10% owner
KKR & Co. Inc.10% owner
KKR Group Holdings Corp.10% owner
KKR Management Holdings Corp10% owner
KKR Management Holdings L.P.10% owner
KKR Genetic Disorder GP LLC10% owner
|
ConversionCommon Stock | 34,253,561 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019173 · doc4.xml · nonDerivative · entry 1 KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner ROBERTS GEORGE R · CIK 0001081715 · 10% owner KRAVIS HENRY R · CIK 0001081714 · 10% owner KKR Management LLC · CIK 0001472694 · 10% owner KKR & Co. Inc. · CIK 0001404912 · 10% owner KKR Group Holdings Corp. · CIK 0001743754 · 10% owner KKR Management Holdings Corp · CIK 0001472692 · 10% owner KKR Management Holdings L.P. · CIK 0001472693 · 10% owner KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 34,253,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date. F2 · ownership.nature: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 23:02 UTC |
VIKING GLOBAL INVESTORS LP10% owner
Viking Global Opportunities GP LLC10% owner
HALVORSEN OLE ANDREAS10% owner
Ott David C.10% owner
Shabet Rose Sharon10% owner
|
ConversionSeries D Preferred Units · Derivative | 50,446,451 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000903423-19-000265 · bbio.xml · derivative · entry 5 VIKING GLOBAL INVESTORS LP · CIK 0001103804 · 10% owner Viking Global Opportunities Illiquid Investments Sub-Master LP · CIK 0001629482 · 10% owner Viking Global Opportunities Portfolio GP LLC · CIK 0001629472 · 10% owner Viking Global Opportunities GP LLC · CIK 0001629476 · 10% owner HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner Ott David C. · CIK 0001621842 · 10% owner Shabet Rose Sharon · CIK 0001711393 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 0 Underlying: Common Stock · 10,178,954 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F1 · price: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F2 · ownership.nature: O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund," and together with VLFM and VGEM, the "Viking Funds"). F3 · ownership.nature: VGP serves as the investment manager of VGEM. Opportunities Portfolio GP is the general partner of Opportunities Fund. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form. F4 · ownership.nature: VGEM directly holds 631,167 shares of Common Stock; VLFM directly holds 251,204 shares of Common Stock; and Opportunities Fund directly holds 25,738,620 shares of Common Stock. F5 · ownership.nature: VGI provides managerial services to the Viking Funds. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares directly held by the Viking Funds. VGP is the investment manager of VGEM. Because of the relationships between VGP and VGEM, VGP may be deemed to beneficially own the shares directly held by VGEM. VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares directly held by VLFM. F6 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Opportunities Fund. F7 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 23:02 UTC |
VIKING GLOBAL INVESTORS LP10% owner
Viking Global Opportunities GP LLC10% owner
HALVORSEN OLE ANDREAS10% owner
Ott David C.10% owner
Shabet Rose Sharon10% owner
|
ConversionSeries C Preferred Units · Derivative | 51,781,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000903423-19-000265 · bbio.xml · derivative · entry 4 VIKING GLOBAL INVESTORS LP · CIK 0001103804 · 10% owner Viking Global Opportunities Illiquid Investments Sub-Master LP · CIK 0001629482 · 10% owner Viking Global Opportunities Portfolio GP LLC · CIK 0001629472 · 10% owner Viking Global Opportunities GP LLC · CIK 0001629476 · 10% owner HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner Ott David C. · CIK 0001621842 · 10% owner Shabet Rose Sharon · CIK 0001711393 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 0 Underlying: Common Stock · 11,736,137 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F1 · price: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F2 · ownership.nature: O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund," and together with VLFM and VGEM, the "Viking Funds"). F3 · ownership.nature: VGP serves as the investment manager of VGEM. Opportunities Portfolio GP is the general partner of Opportunities Fund. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form. F4 · ownership.nature: VGEM directly holds 631,167 shares of Common Stock; VLFM directly holds 251,204 shares of Common Stock; and Opportunities Fund directly holds 25,738,620 shares of Common Stock. F5 · ownership.nature: VGI provides managerial services to the Viking Funds. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares directly held by the Viking Funds. VGP is the investment manager of VGEM. Because of the relationships between VGP and VGEM, VGP may be deemed to beneficially own the shares directly held by VGEM. VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares directly held by VLFM. F6 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Opportunities Fund. F7 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 23:02 UTC |
VIKING GLOBAL INVESTORS LP10% owner
Viking Global Opportunities GP LLC10% owner
HALVORSEN OLE ANDREAS10% owner
Ott David C.10% owner
Shabet Rose Sharon10% owner
|
PurchaseCommon Stock | 4,705,900 | $17.00 | $80,000,300.00 |
DisclosureSEC source: 0000903423-19-000265 · bbio.xml · nonDerivative · entry 3 VIKING GLOBAL INVESTORS LP · CIK 0001103804 · 10% owner Viking Global Opportunities Illiquid Investments Sub-Master LP · CIK 0001629482 · 10% owner Viking Global Opportunities Portfolio GP LLC · CIK 0001629472 · 10% owner Viking Global Opportunities GP LLC · CIK 0001629476 · 10% owner HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner Ott David C. · CIK 0001621842 · 10% owner Shabet Rose Sharon · CIK 0001711393 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 26,620,991 F8 · shares: On June 27, 2019, the Viking Funds acquired an aggregate of 4,705,900 shares of Common Stock at a price of $17.00 per share in connection with the IPO. VGEM acquired 631,167 shares in the IPO, VLFM acquired 251,204 shares in the IPO and Opportunities Fund acquired 3,823,529 shares in the IPO. F2 · ownership.nature: O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund," and together with VLFM and VGEM, the "Viking Funds"). F3 · ownership.nature: VGP serves as the investment manager of VGEM. Opportunities Portfolio GP is the general partner of Opportunities Fund. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form. F4 · ownership.nature: VGEM directly holds 631,167 shares of Common Stock; VLFM directly holds 251,204 shares of Common Stock; and Opportunities Fund directly holds 25,738,620 shares of Common Stock. F5 · ownership.nature: VGI provides managerial services to the Viking Funds. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares directly held by the Viking Funds. VGP is the investment manager of VGEM. Because of the relationships between VGP and VGEM, VGP may be deemed to beneficially own the shares directly held by VGEM. VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares directly held by VLFM. F6 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Opportunities Fund. F7 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 23:02 UTC |
VIKING GLOBAL INVESTORS LP10% owner
Viking Global Opportunities GP LLC10% owner
HALVORSEN OLE ANDREAS10% owner
Ott David C.10% owner
Shabet Rose Sharon10% owner
|
ConversionCommon Stock | 10,178,954 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000903423-19-000265 · bbio.xml · nonDerivative · entry 2 VIKING GLOBAL INVESTORS LP · CIK 0001103804 · 10% owner Viking Global Opportunities Illiquid Investments Sub-Master LP · CIK 0001629482 · 10% owner Viking Global Opportunities Portfolio GP LLC · CIK 0001629472 · 10% owner Viking Global Opportunities GP LLC · CIK 0001629476 · 10% owner HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner Ott David C. · CIK 0001621842 · 10% owner Shabet Rose Sharon · CIK 0001711393 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 21,915,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F2 · ownership.nature: O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund," and together with VLFM and VGEM, the "Viking Funds"). F3 · ownership.nature: VGP serves as the investment manager of VGEM. Opportunities Portfolio GP is the general partner of Opportunities Fund. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form. F4 · ownership.nature: VGEM directly holds 631,167 shares of Common Stock; VLFM directly holds 251,204 shares of Common Stock; and Opportunities Fund directly holds 25,738,620 shares of Common Stock. F5 · ownership.nature: VGI provides managerial services to the Viking Funds. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares directly held by the Viking Funds. VGP is the investment manager of VGEM. Because of the relationships between VGP and VGEM, VGP may be deemed to beneficially own the shares directly held by VGEM. VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares directly held by VLFM. F6 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Opportunities Fund. F7 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 23:02 UTC |
VIKING GLOBAL INVESTORS LP10% owner
Viking Global Opportunities GP LLC10% owner
HALVORSEN OLE ANDREAS10% owner
Ott David C.10% owner
Shabet Rose Sharon10% owner
|
ConversionCommon Stock | 11,736,137 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000903423-19-000265 · bbio.xml · nonDerivative · entry 1 VIKING GLOBAL INVESTORS LP · CIK 0001103804 · 10% owner Viking Global Opportunities Illiquid Investments Sub-Master LP · CIK 0001629482 · 10% owner Viking Global Opportunities Portfolio GP LLC · CIK 0001629472 · 10% owner Viking Global Opportunities GP LLC · CIK 0001629476 · 10% owner HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner Ott David C. · CIK 0001621842 · 10% owner Shabet Rose Sharon · CIK 0001711393 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 11,736,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F2 · ownership.nature: O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund," and together with VLFM and VGEM, the "Viking Funds"). F3 · ownership.nature: VGP serves as the investment manager of VGEM. Opportunities Portfolio GP is the general partner of Opportunities Fund. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form. F4 · ownership.nature: VGEM directly holds 631,167 shares of Common Stock; VLFM directly holds 251,204 shares of Common Stock; and Opportunities Fund directly holds 25,738,620 shares of Common Stock. F5 · ownership.nature: VGI provides managerial services to the Viking Funds. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares directly held by the Viking Funds. VGP is the investment manager of VGEM. Because of the relationships between VGP and VGEM, VGP may be deemed to beneficially own the shares directly held by VGEM. VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares directly held by VLFM. F6 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Opportunities Fund. F7 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 19:02 UTC |
VIKING GLOBAL PERFORMANCE LLC10% owner
Viking Global Equities Master Ltd.10% owner
Viking Long Fund GP LLC10% owner
Viking Long Fund Master Ltd.10% owner
HALVORSEN OLE ANDREAS10% owner
Ott David C.10% owner
Shabet Rose Sharon10% owner
|
ConversionSeries D Preferred Units · Derivative | 50,446,451 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000903423-19-000266 · vgpbbio4.xml · derivative · entry 5 VIKING GLOBAL PERFORMANCE LLC · CIK 0001132625 · 10% owner Viking Global Equities Master Ltd. · CIK 0001759530 · 10% owner Viking Long Fund GP LLC · CIK 0001621607 · 10% owner Viking Long Fund Master Ltd. · CIK 0001621596 · 10% owner HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner Ott David C. · CIK 0001621842 · 10% owner Shabet Rose Sharon · CIK 0001711393 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 0 Underlying: Common Stock · 10,178,954 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F1 · price: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F2 · ownership.nature: O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund," and together with VLFM and VGEM, the "Viking Funds"). F3 · ownership.nature: VGP serves as the investment manager of VGEM. Opportunities Portfolio GP is the general partner of Opportunities Fund. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form. F4 · ownership.nature: VGEM directly holds 631,167 shares of Common Stock; VLFM directly holds 251,204 shares of Common Stock; and Opportunities Fund directly holds 25,738,620 shares of Common Stock. F5 · ownership.nature: VGI provides managerial services to the Viking Funds. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares directly held by the Viking Funds. VGP is the investment manager of VGEM. Because of the relationships between VGP and VGEM, VGP may be deemed to beneficially own the shares directly held by VGEM. VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares directly held by VLFM. F6 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Opportunities Fund. F7 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 19:02 UTC |
VIKING GLOBAL PERFORMANCE LLC10% owner
Viking Global Equities Master Ltd.10% owner
Viking Long Fund GP LLC10% owner
Viking Long Fund Master Ltd.10% owner
HALVORSEN OLE ANDREAS10% owner
Ott David C.10% owner
Shabet Rose Sharon10% owner
|
ConversionSeries C Preferred Units · Derivative | 51,781,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000903423-19-000266 · vgpbbio4.xml · derivative · entry 4 VIKING GLOBAL PERFORMANCE LLC · CIK 0001132625 · 10% owner Viking Global Equities Master Ltd. · CIK 0001759530 · 10% owner Viking Long Fund GP LLC · CIK 0001621607 · 10% owner Viking Long Fund Master Ltd. · CIK 0001621596 · 10% owner HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner Ott David C. · CIK 0001621842 · 10% owner Shabet Rose Sharon · CIK 0001711393 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 0 Underlying: Common Stock · 11,736,137 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F1 · price: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F2 · ownership.nature: O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund," and together with VLFM and VGEM, the "Viking Funds"). F3 · ownership.nature: VGP serves as the investment manager of VGEM. Opportunities Portfolio GP is the general partner of Opportunities Fund. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form. F4 · ownership.nature: VGEM directly holds 631,167 shares of Common Stock; VLFM directly holds 251,204 shares of Common Stock; and Opportunities Fund directly holds 25,738,620 shares of Common Stock. F5 · ownership.nature: VGI provides managerial services to the Viking Funds. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares directly held by the Viking Funds. VGP is the investment manager of VGEM. Because of the relationships between VGP and VGEM, VGP may be deemed to beneficially own the shares directly held by VGEM. VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares directly held by VLFM. F6 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Opportunities Fund. F7 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 19:02 UTC |
VIKING GLOBAL PERFORMANCE LLC10% owner
Viking Global Equities Master Ltd.10% owner
Viking Long Fund GP LLC10% owner
Viking Long Fund Master Ltd.10% owner
HALVORSEN OLE ANDREAS10% owner
Ott David C.10% owner
Shabet Rose Sharon10% owner
|
PurchaseCommon Stock | 4,705,900 | $17.00 | $80,000,300.00 |
DisclosureSEC source: 0000903423-19-000266 · vgpbbio4.xml · nonDerivative · entry 3 VIKING GLOBAL PERFORMANCE LLC · CIK 0001132625 · 10% owner Viking Global Equities Master Ltd. · CIK 0001759530 · 10% owner Viking Long Fund GP LLC · CIK 0001621607 · 10% owner Viking Long Fund Master Ltd. · CIK 0001621596 · 10% owner HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner Ott David C. · CIK 0001621842 · 10% owner Shabet Rose Sharon · CIK 0001711393 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 26,620,991 F8 · shares: On June 27, 2019, the Viking Funds acquired an aggregate of 4,705,900 shares of Common Stock at a price of $17.00 per share in connection with the IPO. VGEM acquired 631,167 shares in the IPO, VLFM acquired 251,204 shares in the IPO and Opportunities Fund acquired 3,823,529 shares in the IPO. F2 · ownership.nature: O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund," and together with VLFM and VGEM, the "Viking Funds"). F3 · ownership.nature: VGP serves as the investment manager of VGEM. Opportunities Portfolio GP is the general partner of Opportunities Fund. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form. F4 · ownership.nature: VGEM directly holds 631,167 shares of Common Stock; VLFM directly holds 251,204 shares of Common Stock; and Opportunities Fund directly holds 25,738,620 shares of Common Stock. F5 · ownership.nature: VGI provides managerial services to the Viking Funds. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares directly held by the Viking Funds. VGP is the investment manager of VGEM. Because of the relationships between VGP and VGEM, VGP may be deemed to beneficially own the shares directly held by VGEM. VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares directly held by VLFM. F6 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Opportunities Fund. F7 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 19:02 UTC |
VIKING GLOBAL PERFORMANCE LLC10% owner
Viking Global Equities Master Ltd.10% owner
Viking Long Fund GP LLC10% owner
Viking Long Fund Master Ltd.10% owner
HALVORSEN OLE ANDREAS10% owner
Ott David C.10% owner
Shabet Rose Sharon10% owner
|
ConversionCommon Stock | 10,178,954 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000903423-19-000266 · vgpbbio4.xml · nonDerivative · entry 2 VIKING GLOBAL PERFORMANCE LLC · CIK 0001132625 · 10% owner Viking Global Equities Master Ltd. · CIK 0001759530 · 10% owner Viking Long Fund GP LLC · CIK 0001621607 · 10% owner Viking Long Fund Master Ltd. · CIK 0001621596 · 10% owner HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner Ott David C. · CIK 0001621842 · 10% owner Shabet Rose Sharon · CIK 0001711393 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 21,915,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7. F2 · ownership.nature: O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund," and together with VLFM and VGEM, the "Viking Funds"). F3 · ownership.nature: VGP serves as the investment manager of VGEM. Opportunities Portfolio GP is the general partner of Opportunities Fund. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form. F4 · ownership.nature: VGEM directly holds 631,167 shares of Common Stock; VLFM directly holds 251,204 shares of Common Stock; and Opportunities Fund directly holds 25,738,620 shares of Common Stock. F5 · ownership.nature: VGI provides managerial services to the Viking Funds. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares directly held by the Viking Funds. VGP is the investment manager of VGEM. Because of the relationships between VGP and VGEM, VGP may be deemed to beneficially own the shares directly held by VGEM. VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares directly held by VLFM. F6 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Opportunities Fund. F7 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.